International | Great Britain

Biotest AG / Miscellaneous


Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.

Biotest: plasmapheresis centre in Dortmund opens

· Seventh centre operated by the Group to obtain blood plasma in Germany
· Following the acquisition of Nabi, 17 collection stations worldwide
· Operation of own donor centres secures long-term supply of high quality

Dreieich, 5.November 2007. PlasmaService Europe, a subsidiary of Biotest
AG, Dreieich, has today opened a new plasmapheresis centre in Germany. The
centre in Dortmund located on Westenhellweg with 24 places will have an
annual capacity of more than 30,000 litres of blood plasma at the final
construction stages. Together with the centre recently taken over in
Aachen, this raises the number of Biotest donor centres in Germany to
seven. Furthermore, Biotest operates another collection centre in Innsbruck
in Austria.

The acquisition of the plasma protein operations of US company Nabi
Biopharmaceuticals Corp. and its nine centres is currently ongoing.
Following the successful completion of the transaction, Biotest will
operate 17 donor centres and therefore cover a major proportion of the
plasma needed using its own capacities.

Human blood plasma is the most important raw material for Biotest's
pharmaceutical products, which comprise around three quarters of annual
sales. The company manufactures medication from individual proteins, which
are used to prevent and treat various diseases of the immune and the
haemopoietic systems as well in emergency medicine. By providing a high
proportion of blood plasma from its own plasmapheresis centres, the company
ensures that it will be affected to a lesser degree by price fluctuations
in the global market. In addition to operating its own centres, Biotest
obtains blood plasma from suppliers with which it has long-standing

During plasmapheresis, the blood is removed from the donor and the plasma
is separated. The cellular components (red blood cells etc.) are then
returned directly to the donor, which means that plasma donations can be
made much more frequently than blood donations.


This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and asset
situation of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
deviation of actual developments from expected developments. The
forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.

About Biotest
Biotest AG, Dreieich, Germany, is a company that researches and
manufactures pharmaceutical, biotherapeutic and diagnostic products and has
specialised in immunology and haematology. In its Pharmaceutical segment,
Biotest develops immunoglobulins, clotting factors and albumins based on
human blood plasma. These are used for diseases of the immune system or
haematopoietic system. In the Biotherapeutic segment, Biotest researches
into the clinical development of monoclonal antibodies, including in the
indications of rheumatoid arthritis and blood cancer. The Diagnostic
segment spans reagents and serology and microbiology systems which are
used, for example, in blood transfusions. Biotest has around 1,200
employees worldwide and its shares are listed in the Frankfurt Stock
Exchange's Prime Standard.

Biotest AG:
Biotest AG, Landsteinerstr. 5, D-63303 Dreieich,
Dr. Marion Wendorff, Tel: +49 (0) 6103 801-520, e-mail:
Fax: +49 (0) 6103 801-347

WKN, ISIN ordinary share: 522720, DE0005227201
WKN, ISIN preference share: 522723, DE0005227235
Listed: Prime Standard/official trading
Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart
05.11.2007 Financial News transmitted by DGAP

Language: English
Issuer: Biotest AG
Landsteinerstr. 5
63303 Dreieich
Phone: +49 - 6103 / 801 - 0
Fax: +49 - 6103 / 801 - 150
ISIN: DE0005227201, DE0005227235
WKN: 522720, 522723
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Stuttgart

End of News DGAP News-Service